Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| 6.08 | |
| 6.07 | |
| - | |
| 6.26 | |
| 5.64 | |
| 2.44-8.84 | |
| 373 M | |
| 61 373 K | |
| 5 759 K | |
| -0.43 | |
| 1.443 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Research and Development Expenses: Increased to $111.3 million for the full year 2023, up from $85.1 million in 2022. General and Administrative Expenses: Rose to $32.0 million for the full year 2023,...
Small-cap growth stocks are highly likely to outperform the broader markets over the next three to five years. One key reason is that the Federal Reserve is widely expected to start cutting interest r...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
